Triple Negative Breast Cancer

Tb434 – T-cell engager Tribody for treating Triple Negative Breast Cancer.

Product Description

Tb434 is a multispecific T-cell engager Tribody™, against a validated targets found in various aggressive subtypes of breast cancer. Tb434 targets the tumour cells and engages T-cells to induce cell killing via an anti-CD3 effector function.

Triple Negative Breast Cancer (TNBC)

Only recently have clinicians concluded that breast cancer is not one disease, but many different forms of cancer all originating in the breast. Depending on its stage of diagnosis, Triple Negative Breast Cancer can be extremely aggressive with a very por prognosis and more likely to recur and metastasize than other subtypes of breast cancer.

This subtype of breast cancer is generally diagnosed based upon the presence, or lack of, three “receptors” known to fuel most breast cancers: estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2).

A Triple Negative Breast Cancer diagnosis means that the tumor is estrogen receptor-negative, progesterone receptor-negative and HER2-negative, thus giving rise to the name “Triple Negative Breast Cancer or TNBC.” Because of its triple negative status, however, triple negative tumors generally do not respond to established receptor targeted treatments.

Depending on the stage of its diagnosis, TNBC can be particularly aggressive, and more likely to recur than other subtypes of breast cancer. It is estimated that 10-20% of all breast cancer patients will develop TNBC, and therefore there is a clear unmet need for developing effective treatments for TNBC.

Biotecnol is testing the efficacy of Tb434 in various subtypes of this highly heterogeneous cancer. Biotecnol is further developing Tb434 as a first-in-class product for treating such a lethal disease.

Disease Facts

  • Triple Negative Breast Cancer is a highly heterogeneous malignancy.
  • TNBC accounts for about 15% of all breast cancer types.
  • TNBC has a characteristic recurrence pattern with the peak risk of recurrence and the majority of deaths occurring in the first 3 and 5 years after the initial treatment, respectively.
  • Comparing to endocrine sensitive tumours, the risk for the late recurrence (beyond 5 years after the diagnosis) decreases by 50%.
  • Some TNBC phenotypes are associated with specific mutations as well as specific genetic profiles. Stratification of patients is therefore a selection criteria for adequate treatment.